EP3700591A1 - Matériau composite biocompatible à introduire dans un organisme humain - Google Patents
Matériau composite biocompatible à introduire dans un organisme humainInfo
- Publication number
- EP3700591A1 EP3700591A1 EP18793653.9A EP18793653A EP3700591A1 EP 3700591 A1 EP3700591 A1 EP 3700591A1 EP 18793653 A EP18793653 A EP 18793653A EP 3700591 A1 EP3700591 A1 EP 3700591A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- composite material
- textile fabric
- elastomeric
- layer
- biocompatible composite
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000002131 composite material Substances 0.000 title claims abstract description 73
- 230000037431 insertion Effects 0.000 title 1
- 238000003780 insertion Methods 0.000 title 1
- 239000000835 fiber Substances 0.000 claims abstract description 53
- 239000004744 fabric Substances 0.000 claims abstract description 49
- 239000000463 material Substances 0.000 claims abstract description 48
- 239000004753 textile Substances 0.000 claims abstract description 48
- 239000013536 elastomeric material Substances 0.000 claims description 36
- 239000002243 precursor Substances 0.000 claims description 25
- 239000007943 implant Substances 0.000 claims description 20
- 229920001296 polysiloxane Polymers 0.000 claims description 19
- 229920000159 gelatin Polymers 0.000 claims description 14
- 235000019322 gelatine Nutrition 0.000 claims description 14
- 108010010803 Gelatin Proteins 0.000 claims description 13
- 239000008273 gelatin Substances 0.000 claims description 13
- 235000011852 gelatine desserts Nutrition 0.000 claims description 13
- 239000004745 nonwoven fabric Substances 0.000 claims description 11
- 238000004132 cross linking Methods 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 239000002657 fibrous material Substances 0.000 claims description 7
- 239000011248 coating agent Substances 0.000 claims description 6
- 238000000576 coating method Methods 0.000 claims description 6
- 239000011148 porous material Substances 0.000 claims description 4
- 229920002379 silicone rubber Polymers 0.000 claims description 4
- 238000009987 spinning Methods 0.000 claims description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
- 206010016717 Fistula Diseases 0.000 claims description 3
- 239000004599 antimicrobial Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000003890 fistula Effects 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- -1 polycapolactones Polymers 0.000 claims description 3
- 229920002101 Chitin Polymers 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- 229920002732 Polyanhydride Polymers 0.000 claims description 2
- 229920000954 Polyglycolide Polymers 0.000 claims description 2
- 229920000331 Polyhydroxybutyrate Polymers 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 239000004373 Pullulan Substances 0.000 claims description 2
- 229920001218 Pullulan Polymers 0.000 claims description 2
- 229940035674 anesthetics Drugs 0.000 claims description 2
- 230000003510 anti-fibrotic effect Effects 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003193 general anesthetic agent Substances 0.000 claims description 2
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims description 2
- 229920005615 natural polymer Polymers 0.000 claims description 2
- 239000005015 poly(hydroxybutyrate) Substances 0.000 claims description 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 2
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 claims description 2
- 239000000622 polydioxanone Substances 0.000 claims description 2
- 229920006149 polyester-amide block copolymer Polymers 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 235000019423 pullulan Nutrition 0.000 claims description 2
- 235000000346 sugar Nutrition 0.000 claims description 2
- 150000008163 sugars Chemical class 0.000 claims description 2
- 229920001971 elastomer Polymers 0.000 abstract description 6
- 239000000806 elastomer Substances 0.000 abstract description 6
- 239000010410 layer Substances 0.000 description 50
- 229920002678 cellulose Polymers 0.000 description 15
- 239000001913 cellulose Substances 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 10
- 238000009864 tensile test Methods 0.000 description 6
- 239000000654 additive Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 5
- 235000010418 carrageenan Nutrition 0.000 description 4
- 229920001525 carrageenan Polymers 0.000 description 4
- 239000000679 carrageenan Substances 0.000 description 4
- 229940113118 carrageenan Drugs 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- 239000000560 biocompatible material Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 229920002301 cellulose acetate Polymers 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 229920001519 homopolymer Polymers 0.000 description 3
- 238000004073 vulcanization Methods 0.000 description 3
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 2
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- LAEKMUKVBJSQBM-CAWKZDFGSA-L dipotassium (2S,3S,4S,5S,6R)-6-[(2S,3S,4R,5S,6R)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [K+].[K+].O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@@H]([C@@H](O)[C@H](O)[C@@H]2O)C([O-])=O)[C@H](O)[C@@H]1O)C([O-])=O LAEKMUKVBJSQBM-CAWKZDFGSA-L 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- AZUXKVXMJOIAOF-UHFFFAOYSA-N 1-(2-hydroxypropoxy)propan-2-ol Chemical compound CC(O)COCC(C)O AZUXKVXMJOIAOF-UHFFFAOYSA-N 0.000 description 1
- TURGQPDWYFJEDY-UHFFFAOYSA-N 1-hydroperoxypropane Chemical compound CCCOO TURGQPDWYFJEDY-UHFFFAOYSA-N 0.000 description 1
- RPZANUYHRMRTTE-UHFFFAOYSA-N 2,3,4-trimethoxy-6-(methoxymethyl)-5-[3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxyoxane;1-[[3,4,5-tris(2-hydroxybutoxy)-6-[4,5,6-tris(2-hydroxybutoxy)-2-(2-hydroxybutoxymethyl)oxan-3-yl]oxyoxan-2-yl]methoxy]butan-2-ol Chemical compound COC1C(OC)C(OC)C(COC)OC1OC1C(OC)C(OC)C(OC)OC1COC.CCC(O)COC1C(OCC(O)CC)C(OCC(O)CC)C(COCC(O)CC)OC1OC1C(OCC(O)CC)C(OCC(O)CC)C(OCC(O)CC)OC1COCC(O)CC RPZANUYHRMRTTE-UHFFFAOYSA-N 0.000 description 1
- JDFDHBSESGTDAL-UHFFFAOYSA-N 3-methoxypropan-1-ol Chemical compound COCCCO JDFDHBSESGTDAL-UHFFFAOYSA-N 0.000 description 1
- SVUDQUZYHLUPQN-UHFFFAOYSA-N 4-n-(2-chloro-7-methoxyacridin-9-yl)-1-n,1-n-diethylpentane-1,4-diamine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=C(Cl)C=C3)C3=NC2=C1 SVUDQUZYHLUPQN-UHFFFAOYSA-N 0.000 description 1
- GKFPPCXIBHQRQT-UHFFFAOYSA-N 6-(2-carboxy-4,5-dihydroxy-6-methoxyoxan-3-yl)oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(OC)C(C(O)=O)O1 GKFPPCXIBHQRQT-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- 229920000148 Polycarbophil calcium Polymers 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- UTKBLLDLHPDWDU-ODZAUARKSA-N acetic acid;(z)-but-2-enedioic acid Chemical compound CC(O)=O.OC(=O)\C=C/C(O)=O UTKBLLDLHPDWDU-ODZAUARKSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 235000010407 ammonium alginate Nutrition 0.000 description 1
- 239000000728 ammonium alginate Substances 0.000 description 1
- KPGABFJTMYCRHJ-YZOKENDUSA-N ammonium alginate Chemical compound [NH4+].[NH4+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O KPGABFJTMYCRHJ-YZOKENDUSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000032798 delamination Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000001761 ethyl methyl cellulose Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229920002529 medical grade silicone Polymers 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 229920003087 methylethyl cellulose Polymers 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229950005134 polycarbophil Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010408 potassium alginate Nutrition 0.000 description 1
- 239000000737 potassium alginate Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000012686 silicon precursor Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 125000005591 trimellitate group Chemical group 0.000 description 1
- PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/12—Mammary prostheses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/20—Larynxes; Tracheae combined with larynxes or for use therewith
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/222—Gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/24—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/48—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/04—Macromolecular materials
- A61L29/044—Proteins; Polypeptides; Degradation products thereof
- A61L29/045—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/04—Macromolecular materials
- A61L29/044—Proteins; Polypeptides; Degradation products thereof
- A61L29/046—Gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/04—Macromolecular materials
- A61L29/044—Proteins; Polypeptides; Degradation products thereof
- A61L29/048—Other specific proteins or polypeptides not covered by A61L29/045 - A61L29/047
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/04—Macromolecular materials
- A61L29/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/08—Materials for coatings
- A61L29/085—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/12—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L29/126—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/146—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/148—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0076—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof multilayered, e.g. laminated structures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2240/00—Manufacturing or designing of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2240/001—Designing or manufacturing processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/18—Modification of implant surfaces in order to improve biocompatibility, cell growth, fixation of biomolecules, e.g. plasma treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/02—Methods for coating medical devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/04—Coatings containing a composite material such as inorganic/organic, i.e. material comprising different phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction
Definitions
- the present invention relates to a composite material for wholly or partially introducing it into a human body and in particular for implantation in a human body.
- the invention further relates to a method for producing the composite material and its use for producing a medical device for complete or partial
- Biocompatibility refers to the property of materials in a biological environment adapted to the situation
- implants have to meet high requirements because they are intended to remain there permanently or at least for a period of a few days as materials implanted in the body.
- Medical implants have the task To support or replace body functions, while in plastic implants, the shape, possibly destroyed, body parts to be restored or changed.
- the silicone often used in implants is basically
- the immune system of the host body is activated after implantation and tries to resorb the foreign material. If the immune cells do not resorb due to the foreign material properties, the body begins to surround the implant with a fibrous sheath and thereby separate from the surrounding tissue. This separation is at least then of concern when the capsule of scar tissue hardens and to
- biocompatible materials for the surface of implants that can interact with the host body. These can be bioresorbable materials that can be decomposed and metabolized by the body's own cells. When these materials are designed as support structures, cells can migrate into these structures to build new, endogenous tissue.
- Supporting structure material is absorbed during this time. There are currently no products on the market that follow this approach. Presumably, this is because the implants would lose their function in the course of absorption.
- the invention is based on the object
- a biocompatible composite material for complete or partial introduction into a human body comprising at least one layer comprising an elastomeric material, and at least one disposed on this layer and the surface of the
- Fabric bioresorbable fibers which are at least partially embedded in the position of elastomeric material.
- the bond between the fabric and the elastomeric material may be communicated through the bioabsorbable fibers which are at least partially embedded in the layer of elastomeric material.
- This embedding can be obtained, for example, by applying the textile fabric to an elastomeric precursor material, for example an unvulcanized silicone layer, and pressing it into it.
- the impressions have the purpose of introducing the fibers of the textile fabric into the precursor layer.
- the composite for example by vulcanization of the precursor to form the solidified elastomeric material and cured in its elastomeric portion.
- elastomeric material can be a stable composite material with high
- a high layer adhesion means that the composite material can be handled in the usual way and, for example, can be introduced into the human body without the adhesion between the elastomeric material and the textile material
- the composite material it is advantageous for the composite material to have a surface formed from a bioresorbable fiber-containing fabric, since biocompatibility-enhancing interaction with the surrounding tissue is possible as a result.
- Textile fabrics have a three-dimensional structure due to their fiber structure. As explained above, structured surfaces can reduce the frequency of occurrence of
- Nonwovens are particularly preferred since the fibers are present there as a random knit and have a strong three-dimensional structuring.
- One possible measure of the extent of the three-dimensional structuring of the surface is the average pore size of the textile fabric.
- the textile fabric preferably has an average pore size of 50 ⁇ to 300 ⁇ , preferably from 70 to 250 ⁇ , more preferably from 100 to 200 ⁇ on.
- the pore size is measured before introduction into the elastomeric material. It is measured according to ASTM E 1294 (1989).
- the bioresorbable fibers may be resorbed after being introduced into the body over time. It is advantageous that the bioresorbable fibers are also present within the elastomeric layer, since in the bioresorption cavities are formed in the position of elastomeric material, comparable to a dynamically changing, three-dimensional structuring on the surface of the composite material. Over time, the layer of elastomeric material is thus provided with cavities.
- the formation of the cavities takes place continuously, with preferably more than half, more preferably more than 75% by weight, in particular more than 90% by weight, of the textile fabric being absorbed after 60 days.
- the layer of elastomeric material is successively to the surface layer of
- the composite material according to the invention allows ingrowth of body tissue and consequently a stepwise replacement of the textile
- Another advantage of the composite material according to the invention is that at least in the first time after introduction into the body by the bioresorbable coating, the surface of the elastomeric material in the body can be separated from the tissue, what its acceptance and
- the composite material according to the invention is characterized in that it can have excellent elasticity due to the use of an elastomeric material. As a result, a good adaptation to deforming forces outside and inside the body can be ensured.
- the high elasticity is particularly advantageous if the
- Composite material for example, as an implant is to be introduced through the smallest possible body opening in the body. Its high elasticity allows the composite material to deform severely, for example, to be lengthened so as to be able to be introduced into the body through the small body opening.
- the composite material is characterized by an elasticity measured according to DIN 53504 S2 at a rate of 200 mm / min from 50% to 500%, preferably from 200% to 500%, more preferably from 400% to 500%. It was surprising for the person skilled in the art that the composite material according to the invention can have such a high elasticity. In particular, it was expected that at
- the beneficial effects come into effect the longer the time that the composite material is to remain in the human body.
- the effects caused by the three-dimensionally structured surface become more pronounced the greater the proportion of the textile fabric on the surface of the implant.
- the proportion of the textile fabric at the surface of the composite material is more than 50%, more preferably more than 70%, even more preferably more than 90%, and in particular 100%.
- the above values refer to the state before introduction into the human body.
- the bioresorbable fibers may comprise a wide variety of fiber materials.
- the fibers comprise bioresorbable fiber materials selected from the group consisting of natural polymers, proteins, peptides, sugars, chitosan, chitin, gelatin, collagen, polyvinyl alcohol, polyvinylpyrrolidone, dextran, pullulan, hyaluronic acid, polycapolactones, polylactides, polyglycolides, polyhydroxyalkanolates, polydioxanones,
- the fiber material consists entirely of the abovementioned materials, with customary auxiliaries, for example catalyst residues, also being present in the fiber material.
- the fibers exclusively comprise gelatin as bioresorbable fiber material and / or consists of at least 70% by weight, and / or at least 80% by weight, and / or at least 90% by weight, and / or At least 95% by weight of gelatin, in each case based on the total weight of the bioresorbable fibers.
- Porcine gelatin is preferred according to the invention, since these are not
- BSE bovine spongiform encephalopathy
- the bioresorbable fibers usually contain water.
- the bioresorbable fibers additionally contain at least one hydrophilic additive.
- the hydrophilic additive is selected from the group consisting of: carbomer [9003-01 -4], ethyl acetate, polymer with 1-ethenyl-2-pyrrolidinone [25086-89-9], 1-ethenyl-2-pyrrolidinone homopolymer [9003- 39-8], cellulose
- hydroxypropylmethylether [9004-65-3], polycarbophil [9003-97-8], 1-ethylen-2-pyrrolidinone homopolymer [9003-39-8], methylcellulose (E 461), ethylcellulose (E 462), hydroxypropylcellulose (E 463 ), Hydroxypropylmethylcellulose (E 464), methylethylcellulose (E 465), sodium carboxymethylcellulose (E 466),
- Carboxymethylcellulose cellulose acetate (e.g., available from Chisso, Eastman), cellulose acetate butyrate (e.g., available from Eastman, FMC),
- Cellulose acetate maleate cellulose acetate phthalate (e.g., available from Eastman, FMC, Parmentier), cellulose acetate trimellitates (e.g., available from Eastman, Parmentier), cellulose fatty acid esters (cellulose dilaurate, cellulose dipalmitate, cellulose distearate, cellulose monopalmitate, cellulose monostearate,
- pregelatinized starch dextrin [9004-53-9], cellulose, 2-hydroxyethyl ether [9004-62-0], hydroxyethylmethylcellulose [9032-42-2], cellulose, 2-hydroxypropyl ether [9004-64-2], cellulose, 2 Hydroxypropyl ether (low substituted) [9004-64-2], hydroxypropyl starch [1 13894-92-1], ethenol,
- Polyethylene oxide polyethylene glycol.
- hydrophilic Additives for example, in an amount of from 0.1% by weight to 30% by weight,
- Particularly preferred according to the invention are sodium hyaluronate,
- Hyaluronic acid polyethylene oxide and polyethylene glycol.
- hydrophilic additives are used with them a particularly high initial wettability of, for example, less than 10 seconds, preferably less than 5 seconds, more preferably less than 2 seconds can be achieved.
- the high initial wettability is advantageous to the textile
- Composite material in the human body may be particularly useful if one or more drugs selected from the group consisting of antimicrobials, anesthetics, anti-inflammatory agents, Antinarbensch, antifibrotic agents, chemotherapeutic agents and leukotriene inhibitors present in and / or on the bioresorbable fibers.
- Antimicrobials and / or antibiotics are particularly suitable for preventing infection.
- the bioresorbable fibers may be continuous filaments or staple fibers, continuous filaments being understood to be fibers of theoretically unlimited length and staple fibers are fibers of limited length.
- the bioresorbable fibers are formed as continuous filaments and / or staple fibers with a minimum length of 5 mm, for example of 5 mm to 10 cm. In practical
- the textile fabric has a basis weight of from 10 to 300 g / m 2 , preferably from 50 to 200 g / m 2 , more preferably from 70 to 150 g / m 2 .
- a sheet with these basis weights has sufficient stability to be applied wrinkle-free on a variety of layers of elastomeric material three-dimensional geometry can.
- the textile fabric measured with a width of 20 mm can be given a maximum tensile force of at least 0.5 to 100N, preferably from 1.0 to 50N, more preferably from 2.0 to 30N. This is advantageous because a minimum maximum tensile force for the processing of the textile
- the period of time within which the textile fabric is absorbed depends on various parameters and, among other things, on the thickness of the textile fabric. Against this background, it has proved to be expedient in most cases the textile fabric, with an average thickness of less than 2 mm, preferably from 5 to 700 nm
- the textile fabric may in principle comprise one or more fiber layers. Particularly preferably, it comprises only one fiber layer, since adhesion problems, as often occur between multiple fiber layers, can be avoided.
- the textile fabric can also be present in a wide variety of embodiments, for example as a woven or knitted fabric or as a nonwoven fabric.
- Nonwovens are particularly preferred according to the invention, in particular nonwovens produced in a rotary spinning process. In rotary spinning processes nonwovens can be produced, for example, by using a fiber material
- containing fluid which as a melt, solution
- Dispersion or suspension may be present, the fluid spun by rotation spinning, stretched and deposited into a nonwoven. This technique can be used at low temperatures up to 60 ° C. This allows a particularly gentle processing of the biopolymers and active ingredients.
- Nonwovens which are particularly preferred according to the invention are nonwovens, as described in WO 2008/107126 A1, WO 2009/036958 A1, EP 2 409 718 A1, EP 2 042 199 A1, EP2129339 B1, CA2682190C.
- WO 2008/107126 A1 WO 2009/036958 A1
- EP 2 409 718 A1 EP 2 042 199 A1
- EP2129339 B1 EP2129339 B1
- CA2682190C CA2682190C.
- the layer of elastomeric material may comprise a wide variety of elastomeric materials. Of these materials, silicone elastomers, particularly medical grade silicone elastomers, are particularly preferred because they are relatively inert and do not react with the body.
- the layer of elastomeric material preferably comprises at least 70% by weight and / or at least 90% by weight and / or at least 95% by weight of the abovementioned silicone elastomers. Most preferably, the layer of elastomeric material to 100 wt.% Of silicone elastomers medical grade, which may contain conventional additives.
- the thickness of the layer comprising the elastomeric material may vary depending on the materials used and the intended use. As a rule, have thicknesses in the range of 100 ⁇ to 5000 ⁇ , preferably from 100 ⁇ to 4000 ⁇ more preferably from 100 ⁇ to 3000 ⁇ proven.
- the layer of elastomeric material may in principle comprise one or more layers
- the composite material has a
- the carrier layer is made of a biocompatible material, since this can remain in the composite material and meets the requirements for introduction into the human body.
- the carrier layer preferably consists of an elastomeric material, in particular silicone. It is also conceivable the use of others
- Carrier layers such as films, plates or impression body.
- Another object of the present invention is the formation of the composite material as a medical device to complete or partial
- an implant is to be understood as a material implanted in the body which is to remain there permanently or at least for a period of time, for example from a few days to 10 years.
- a particularly preferred embodiment of the invention that is
- Composite material as a medical device for a body access in particular as a catheter, and has the following features: the layer of elastomeric material is in the form of a shell, the bioresorbable fibers having textile fabrics is arranged as a coating on the outside of the shell.
- the entire surface of the coating can be formed, so that the aforementioned advantages can be exploited particularly efficiently.
- the coating completely covers the outside of the envelope.
- the soft tissue implant is shaped so that it can fill a cavity in shape and size in the human body.
- the composite material according to the invention can in a preferred
- the first method step comprises providing a carrier layer.
- the carrier layer preferably consists of an elastomeric material, in particular silicone. It is also conceivable the use of others
- the second method step comprises applying a biocompatible elastomeric precursor material, in particular unvulcanized silicone, to one side of the carrier layer.
- a biocompatible elastomeric precursor material in particular unvulcanized silicone
- elastomeric precursor material a wide variety of materials, such as unvulcanized and / or incompletely vulcanized silicone can be used. These materials can be converted into elastomeric materials by crosslinking in the form of vulcanization.
- silicone in the carrier layer and an elastomeric silicone precursor material is advantageous that forms a particularly homogeneous connection between the layers, since then both layers have the same properties.
- the third method step comprises the application of a bioresorbable fibers having textile fabric on the elastomeric precursor material such that the fibers of the fabric at least partially penetrate into the elastomeric precursor material.
- the penetration of the fibers of the textile fabric into the elastomeric precursor material can be accomplished, for example, by pressurizing the composite of textile fabric and elastomeric precursor material.
- the elastomeric precursor material preferably has a viscosity of 200 mPa * s to 4000 mPa * s, more preferably from 300 mPa * s to 3000 mPa * s and in particular from 500 mPa * s to 2000 mPa * s.
- a textile fabric are preferably the above-mentioned textile
- the fourth process step comprises crosslinking the elastomeric precursor material to an elastomeric material.
- the crosslinking can be easily carried out by heating (vulcanization). It was surprising to the person skilled in the art that the crosslinking also works in the presence of a gelatin-containing textile fabric, since gelatin
- Another object of the present invention is therefore the use of the composite material according to the invention for producing a
- Medical device for complete or partial introduction into the human body in particular as an implant, for example as
- Voice prosthesis and / or for a body access for example as a catheter or fistula adapter.
- this also includes the medical device itself.
- MED-6400A component A
- MED-6400B component B
- NuSil technology Components A and B are mixed at a weight ratio of 1: 1 at room temperature. The mixture is further processed bubble-free.
- the resulting elastomeric precursor material is poured onto the surface of a POM plate as a support layer with an area of 225 cm 2 .
- the elastomeric precursor material coated plate is kept level for 30 minutes to level and evaporate the solvent.
- a gelatin fleece is placed on the surface of the coated plate.
- the gelatin nonwoven composite and silicone coated POM sheet is produced by crosslinking the elastomeric precursor. This is done in a programmable oven with the following
- a silicone / gelatin composite nonwoven fabric is obtained by peeling off the POM plate.
- Tensile tests are carried out for the resultant composite material according to the invention using a tensile testing machine according to DIN 53504 S2 with a head speed of 200 mm / min.
- FIG. 1 Result tensile test of pure silicone layer as reference FIG. 2: result of tensile test of the composite material from example 1
- FIG. 3 Microscopic image of the surface of the composite material from Example 1 after two weeks of storage at 37 ° C. in PBS.
- FIG. 4 Schematic cross-section of a device according to the invention
- Fig. 5 Schematic cross-section of a device according to the invention
- Fig.6 Microscopic view of the sectional view of a
- FIG. 1 shows as a reference the result of a tensile test with a pure silicone layer.
- FIG. 2 shows the result of a tensile test of the composite material from Example 1.
- the gelatin nonwoven in the composite causes a high
- FIG. 4 shows the schematic cross section of a device according to the invention
- Composite material (1) comprising a layer (2) of an elastomeric
- FIG. 5 shows the schematic cross section of a device according to the invention
- Composite material (1) in its embodiment as a catheter.
- the catheter has a sheath (4) of elastomeric material, here silicone.
- elastomeric material here silicone.
- the catheter on a bioresorbable fibers exhibiting textile fabric (3), wherein the bioresorbable fibers, the sheath (4) made of elastomeric material at least partially
- FIG. 6 shows an electron micrograph of the sectional view of a composite material according to the invention.
- Material here silicone, is a gelatine fleece as textile fabric
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Composite Materials (AREA)
- Materials Engineering (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
Abstract
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102017009989.8A DE102017009989A1 (de) | 2017-10-26 | 2017-10-26 | Biokompatibles Verbundmaterial zum Einbringen in einen menschlichen Körper |
| PCT/EP2018/079394 WO2019081700A1 (fr) | 2017-10-26 | 2018-10-26 | Matériau composite biocompatible à introduire dans un organisme humain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP3700591A1 true EP3700591A1 (fr) | 2020-09-02 |
Family
ID=64024038
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP18793653.9A Withdrawn EP3700591A1 (fr) | 2017-10-26 | 2018-10-26 | Matériau composite biocompatible à introduire dans un organisme humain |
| EP18795509.1A Withdrawn EP3700592A1 (fr) | 2017-10-26 | 2018-10-26 | Implant partie molle biocompatible |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP18795509.1A Withdrawn EP3700592A1 (fr) | 2017-10-26 | 2018-10-26 | Implant partie molle biocompatible |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20200289715A1 (fr) |
| EP (2) | EP3700591A1 (fr) |
| JP (2) | JP2021500178A (fr) |
| CN (2) | CN111278474A (fr) |
| BR (2) | BR112020006403A2 (fr) |
| DE (1) | DE102017009989A1 (fr) |
| RU (2) | RU2739357C1 (fr) |
| WO (2) | WO2019081700A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7329384B2 (ja) * | 2019-08-08 | 2023-08-18 | グンゼ株式会社 | 組織再生基材 |
| CN116056663A (zh) * | 2020-08-04 | 2023-05-02 | Bvw控股公司 | 微结构软组织移植 |
| EP4292618A4 (fr) * | 2021-02-09 | 2025-01-08 | Shin-Etsu Chemical Co., Ltd. | Dispositif contenant de la gélatine |
| CN115770125A (zh) * | 2021-09-08 | 2023-03-10 | 苏州诺普再生医学有限公司 | 一种3d打印多孔鼻部整形假体 |
| CN120570716B (zh) * | 2025-08-05 | 2025-11-04 | 四川大学华西医院 | 一种植入假体和义肢密封的固定装置 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0305052A1 (fr) * | 1987-07-30 | 1989-03-01 | Dow Corning Kabushiki Kaisha | Peau artificielle et méthode pour sa production |
| US6420285B1 (en) * | 1994-11-23 | 2002-07-16 | Bba Nonwovens Simpsonville, Inc. | Multicomponent fibers and fabrics made using the same |
| US5716404A (en) | 1994-12-16 | 1998-02-10 | Massachusetts Institute Of Technology | Breast tissue engineering |
| GB9717433D0 (en) * | 1997-08-19 | 1997-10-22 | Univ Nottingham | Biodegradable composites |
| US6638308B2 (en) | 1997-10-10 | 2003-10-28 | John D. Corbitt, Jr. | Bioabsorbable breast implant |
| EP1263356B1 (fr) * | 2000-03-14 | 2010-01-27 | Ossur HF | Appareil et procede de fabrication d'un manchon d'aspiration prothetique |
| DE102007011606A1 (de) | 2007-03-02 | 2008-09-04 | Carl Freudenberg Kg | Faser-Wirrgelege |
| US8911765B2 (en) | 2007-03-29 | 2014-12-16 | Tyrx, Inc. | Biodegradable, polymer coverings for breast implants |
| DE102007044648B4 (de) | 2007-09-18 | 2020-11-26 | Carl Freudenberg Kg | Bioresorbierbarer Gelatinevliesstoff |
| DE102008033327A1 (de) * | 2008-07-16 | 2010-01-21 | Bayer Innovation Gmbh | Kieselsol-Material mit mindestens einem therapeutisch aktiven Wirkstoff zur Herstellung von biologisch degradierbaren und/oder resorbierbaren Kieselgel-Materialien für die Humanmedizin und/oder Medizintechnik |
| AU2009282389B2 (en) * | 2008-08-13 | 2015-04-23 | Allergan, Inc. | Soft filled prosthesis shell with discrete fixation surfaces |
| US20100249924A1 (en) | 2009-03-27 | 2010-09-30 | Allergan, Inc. | Bioerodible matrix for tissue involvement |
| DE102009037565A1 (de) * | 2009-08-14 | 2011-02-24 | Mavig Gmbh | Beschichtete Mikrofaserbahn und Verfahren zur Herstellung derselben |
| US20120041555A1 (en) * | 2010-05-10 | 2012-02-16 | Allergan, Inc. | Silicone implant with imprinted texture |
| US8579990B2 (en) * | 2011-03-30 | 2013-11-12 | Ethicon, Inc. | Tissue repair devices of rapid therapeutic absorbency |
| WO2013048978A1 (fr) * | 2011-09-26 | 2013-04-04 | Allergan, Inc. | Implant en silicone texturé |
| US8556968B2 (en) * | 2011-11-09 | 2013-10-15 | Ideal Implant Incorporated | Breast implant with low coefficient of friction between internal shells in an aqueous fluid environment |
| JP5768824B2 (ja) * | 2013-03-06 | 2015-08-26 | 信越化学工業株式会社 | 発泡性シリコーンゴム組成物及びシリコーンゴムスポンジ |
| DE102014002232B4 (de) * | 2014-02-21 | 2019-10-02 | Carl Freudenberg Kg | Mikrofaser-Verbundvliesstoff |
| WO2016103049A1 (fr) * | 2014-12-26 | 2016-06-30 | Resorbium Ltd | Implants médicaux biocomposites renforcés de fibres continues |
| ES2584405A1 (es) * | 2016-06-08 | 2016-09-27 | Universitat Politècnica De València | Compuesto no tejido bioelastómero |
-
2017
- 2017-10-26 DE DE102017009989.8A patent/DE102017009989A1/de not_active Ceased
-
2018
- 2018-10-26 US US16/758,858 patent/US20200289715A1/en not_active Abandoned
- 2018-10-26 EP EP18793653.9A patent/EP3700591A1/fr not_active Withdrawn
- 2018-10-26 JP JP2020523350A patent/JP2021500178A/ja not_active Withdrawn
- 2018-10-26 BR BR112020006403-3A patent/BR112020006403A2/pt not_active IP Right Cessation
- 2018-10-26 WO PCT/EP2018/079394 patent/WO2019081700A1/fr not_active Ceased
- 2018-10-26 EP EP18795509.1A patent/EP3700592A1/fr not_active Withdrawn
- 2018-10-26 BR BR112020006394-0A patent/BR112020006394A2/pt not_active IP Right Cessation
- 2018-10-26 RU RU2020116760A patent/RU2739357C1/ru active
- 2018-10-26 CN CN201880066805.2A patent/CN111278474A/zh active Pending
- 2018-10-26 US US16/758,861 patent/US20200289716A1/en not_active Abandoned
- 2018-10-26 CN CN201880066811.8A patent/CN111315418A/zh active Pending
- 2018-10-26 RU RU2020117044A patent/RU2020117044A/ru not_active Application Discontinuation
- 2018-10-26 JP JP2020523247A patent/JP2021500170A/ja not_active Withdrawn
- 2018-10-26 WO PCT/EP2018/079407 patent/WO2019081708A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| RU2739357C1 (ru) | 2020-12-23 |
| WO2019081700A1 (fr) | 2019-05-02 |
| EP3700592A1 (fr) | 2020-09-02 |
| CN111315418A (zh) | 2020-06-19 |
| BR112020006394A2 (pt) | 2020-09-24 |
| BR112020006403A2 (pt) | 2020-09-24 |
| JP2021500178A (ja) | 2021-01-07 |
| WO2019081708A1 (fr) | 2019-05-02 |
| CN111278474A (zh) | 2020-06-12 |
| DE102017009989A1 (de) | 2019-05-02 |
| RU2020117044A3 (fr) | 2021-11-26 |
| JP2021500170A (ja) | 2021-01-07 |
| US20200289716A1 (en) | 2020-09-17 |
| RU2020117044A (ru) | 2021-11-26 |
| US20200289715A1 (en) | 2020-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3700591A1 (fr) | Matériau composite biocompatible à introduire dans un organisme humain | |
| EP2688533B1 (fr) | Pansement primaire destiné à soigner des plaies en maintenant un milieu humide, et son procédé de fabrication | |
| EP1948260B1 (fr) | Materiau composite utilise en particulier en medecine et procede de production associe | |
| EP1457552B1 (fr) | Support pour culture de cellules et tissus pour la préparation d'un implant et implant contenant cet support | |
| DE69801442T2 (de) | Komposit-prothese zur verhinderung postchirurgischer verklebung und verfahren zu ihrer herstellung | |
| DE69524501T2 (de) | Mit einen Heparin enhaltendes Kollagendichtmittel imprägniertes Gefässtransplantat | |
| DE69804104T2 (de) | Komposit-prothese zur verhinderung postchirurgischer verklebung und verfahren zu ihrer herstellung | |
| DE69426414T2 (de) | Implantatmaterial | |
| EP2322232B1 (fr) | Procédé destiné à la fabrication d'un pansement en forme de couche | |
| DE202007019670U1 (de) | Bioresorbierbare Wundauflagen | |
| EP3261685B1 (fr) | Pansement à base de collagène et procédé pour le produire | |
| DE69103076T2 (de) | Sehnenbandprothese und Verfahren zur Herstellung. | |
| EP2686028B1 (fr) | Mélange de granulats, comprenant deux granulats différents, pour distraction de cal artificielle | |
| EP1252905B1 (fr) | Patch implantable résorbable, son procédé de préparation et son utilisation | |
| DE102012201094A1 (de) | Flexible Gefäßprothese und Verfahren zu ihrer Herstellung | |
| EP2252238A1 (fr) | Dispositif comprenant un agent de gonflement et une enveloppe pour la distraction du cal artificielle | |
| DE102010020663A1 (de) | Medizinisches Hohlkörperimplantat | |
| DE102008014560A1 (de) | Vorrichtung, umfassend ein Quellmittel und eine Ummantelung, zur künstlichen Kallusdistraktion | |
| EP3883496B1 (fr) | Implant ophtalmologique comportant un système de distribution de principe actif et procédé de fabrication d'un tel implant ophtalmologique | |
| DE4416357C2 (de) | Wundauflage | |
| DE102010020662A1 (de) | Medizinisches Implantat | |
| DE102015102598B4 (de) | Kollagenhaltige Wundauflage sowie Verfahren zu deren Herstellung | |
| WO2007085391A1 (fr) | Structure et utilisation de cette structure en tant que pansement de contact direct avec la plaie | |
| EP4587074A1 (fr) | Corps d'implant osseux et sa méthode de production | |
| EP4232103A1 (fr) | Matériau bidimensionnel pour le traitement médical d'une zone de plaie |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20200313 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20220503 |